Sientra (SIEN) Getting Favorable Press Coverage, Study Shows
Media headlines about Sientra (NASDAQ:SIEN) have trended positive this week, according to Accern Sentiment. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Sientra earned a media sentiment score of 0.28 on Accern’s scale. Accern also assigned news stories about the medical instruments supplier an impact score of 47.9274147608834 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:
- Sientra (SIEN) Price Target Cut to $18.00 by Analysts at Canaccord Genuity (americanbankingnews.com)
- Sientra (SIEN) Posts Quarterly Earnings Results, Misses Expectations By $0.21 EPS (americanbankingnews.com)
- Sientra Reports Fourth Quarter and Full Year 2017 Financial Results (finance.yahoo.com)
- Cosmetic Implants Market – Trends, Outlook (openpr.com)
- ValuEngine Lowers Sientra (SIEN) to Sell (americanbankingnews.com)
Several brokerages have recently issued reports on SIEN. BidaskClub raised Sientra from a “sell” rating to a “hold” rating in a report on Friday, December 15th. Zacks Investment Research upgraded Sientra from a “sell” rating to a “hold” rating in a research note on Tuesday, January 2nd. ValuEngine upgraded Sientra from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. Canaccord Genuity restated a “buy” rating and issued a $19.00 price target on shares of Sientra in a research note on Friday, January 5th. Finally, Lake Street Capital lowered Sientra from a “buy” rating to a “hold” rating and cut their price target for the company from $15.00 to $11.00 in a research note on Wednesday, February 21st. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $13.75.
Sientra (NASDAQ:SIEN) last posted its quarterly earnings data on Tuesday, March 13th. The medical instruments supplier reported ($0.92) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.71) by ($0.21). Sientra had a negative return on equity of 68.82% and a negative net margin of 169.77%. The firm had revenue of $11.10 million for the quarter, compared to analysts’ expectations of $11.90 million. During the same quarter last year, the firm posted ($0.43) earnings per share. Sientra’s quarterly revenue was up 70.8% on a year-over-year basis. analysts anticipate that Sientra will post -3.24 earnings per share for the current year.
WARNING: This article was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.thecerbatgem.com/2018/03/14/sientra-sien-getting-favorable-press-coverage-study-shows.html.
Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.